Open Access
| Numéro |
Med Sci (Paris)
Volume 35, Numéro 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
|
|
|---|---|---|
| Page(s) | 1008 - 1013 | |
| Section | Les anticorps dans les maladies autres qu’oncologiques | |
| DOI | https://doi.org/10.1051/medsci/2019200 | |
| Publié en ligne | 6 janvier 2020 | |
- Salazar G, Zhang N, Fu T-M, et al., Antibody therapies for the prevention and treatment of viral infections. NPJ Vaccines. 2017;2:19. [CrossRef] [PubMed] [Google Scholar]
- Pelegrin M, Naranjo-Gomez M, Piechaczyk M , Antiviral monoclonal antibodies: can they be more than simple neutralizing agents? Trends Microbiol. 2015;23:653–665. [Google Scholar]
- Tang PK , Palivizumab prophylaxis in preterm infants. Lancet Respir Med. 2017;5:171. [PubMed] [Google Scholar]
- Sloan SE, Hanlon C, Weldon W, et al., Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine. 2007;25:2800–2810. [CrossRef] [PubMed] [Google Scholar]
- Carrillo J, Clotet B, Blanco J , Antibodies and antibody derivatives: new partners in HIV eradication strategies. Front Immunol. 2018;9:2429. [CrossRef] [PubMed] [Google Scholar]
- Schoofs T, Klein F, Braunschweig M, et al., HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science. 2016;352:997–1001. [Google Scholar]
- Caskey M, Schoofs T, Gruell H, et al., Antibody 10–1074 suppresses viremia in HIV-1-infected individuals. Nat Med. 2017;23:185–191. [CrossRef] [PubMed] [Google Scholar]
- Nishimura Y, Martin MA , Of mice, macaques, and men: broadly neutralizing antibody immunotherapy for HIV-1. Cell Host Microbe. 2017;22:207–216. [CrossRef] [PubMed] [Google Scholar]
- Yamamoto BJ, Shadiack AM, Carpenter S, et al., Obiltoxaximab prevents disseminated Bacillus anthracis infection and improves survival during pre- and postexposure prophylaxis in animal models of inhalational anthrax. Antimicrob Agents Chemother. 2016;60:5796–5805. [CrossRef] [PubMed] [Google Scholar]
- Migone TS, Subramanian GM, Zhong J, et al., Raxibacumab for the treatment of inhalational anthrax. N Engl J Med. 2009;361:135–144. [Google Scholar]
- Lowy I, Molrine DC, Leav BA, et al., Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362:197–205. [Google Scholar]
- Delmas Y, Vendrely B, Clouzeau B, et al., Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrol Dial Transplant. 2014;29:565–572. [CrossRef] [PubMed] [Google Scholar]
- Wagner EK, Maynard JA , Engineering therapeutic antibodies to combat infectious diseases. Curr Opin Chem Eng. 2018;19:131–141. [CrossRef] [PubMed] [Google Scholar]
- Kohler PL, Greenwood SD, Nookala S, et al., Staphylococcus aureus isolates encode variant staphylococcal enterotoxin B proteins that are diverse in superantigenicity and lethality. PloS One. 2012;7:e41157. [CrossRef] [PubMed] [Google Scholar]
- Ali SO, Yu XQ, Robbie GJ, et al., Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults. Clin Microbiol Infect. 2019;25(629):e1–e6. [Google Scholar]
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.